July 17, 2024 01:38 AM EDTUpdated 06:29 AM
People
R&D
Cell/Gene Tx

Cari­bou to slash pre­clin­i­cal al­lo­gene­ic CAR-NK work, lay off 12% of staff

Kyle LaHucik

Senior Reporter

Lei Lei Wu

News Reporter

Cari­bou Bio­sciences is cut­ting its CAR-NK re­search and lay­ing off 21 em­ploy­ees, or 12% of its staff, the com­pa­ny an­nounced Tues­day.

“We are un­der­tak­ing this …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RA Cap­i­tal and For­bion set up new au­toim­mune biotech with bis­pe­cif­ic from Ko­re­an start­up

Oculis clos­es Phase 3 eye drop tri­al due to 'ad­min­is­tra­tive er­ror' from third par­ty

Swiss biotech's in­hibitor of can­cer dri­ver shows promise in rare bleed­ing dis­or­der

Pfiz­er un­veils di­rect-to-con­sumer push for Covid, flu and mi­graine treat­ments

Once one of im­muno-on­col­o­gy's next great hopes, CD47 faces fi­nal shots on goal

Ma­jor Gala­pa­gos in­vestor says it will push board on com­pa­ny's 'per­for­mance' and 's­trate­gic op­por­tu­ni­ties'

A service from the Financial Times